REDDIE Consortium Holds Annual General Assembly Meeting 2025

On November 6, members of the REDDIE consortium gathered for the regular General Assembly meeting to review project progress and discuss upcoming milestones and deliverables. Representatives from all partner institutions joined the meeting and shared updates within their work packages.

As the project enters its final year, the meeting provided an important opportunity to reflect on achievements to date and to align on upcoming objectives. REDDIE Project Manager Mirna Vela from RISE opened the session, providing an overview of deliverables due by the end of the year and outlining key tasks leading up to the project’s conclusion.

Discussions focused on the continued advancement of methodologies using real-world data (RWD) to complement traditional randomised controlled trials (RCTs). By leveraging data from national registries across Sweden, Denmark, Germany, and the UK, the consortium is evaluating how RWD can enhance the understanding of efficacy, safety, and cost-effectiveness of diabetes prevention and treatment technologies. The integration of data from devices, wearables, and electronic health records further strengthens these analyses and supports the development of future regulatory guidelines for RWD assessment.

Looking ahead, the consortium is preparing for the MetReal Multistakeholder Meeting, organised by the Danish Medicines Agency in March 2026, which will bring together diverse perspectives to discuss the use of real-world evidence in healthcare decision-making. The team is also planning for the Mount Hood Challenge 2026, an important event co-organised by REDDIE that will explore innovative modelling approaches in diabetes research.

The next in-person consortium meeting is scheduled for April 2026, hosted by RISE, where partners will review the project’s final outcomes and ensure alignment toward its closing stages.